Enquirer Consulting Group

Reachable Buyer Map

Prepared for Dr. Balamurugan K · Malladi Drugs and Pharmaceuticals · August 2026
An active ingredient and custom chemistry supplier has two buyers who rarely sit in the same meeting: the regulatory and technical seat that qualifies a source, and the sourcing seat that signs for it. Here is where those seats sit across the regulated markets, roughly how many companies are in each, and where the reach is thinnest. It describes the market rather than your business, and there is nothing to buy at the end of it.
Finished-dose manufacturers, United States
The market where a filed dossier does most of the qualifying work before anyone speaks. Qualification is slow and switching is rare, which makes the moment of qualification the whole opportunity.
Who signs: head of strategic sourcing or ingredient procurement, vice president of external manufacturing, formulation development director, regulatory affairs lead, and quality assurance for vendor approval.
600 to 800
US companies operating registered drug manufacturing sites; roughly 1,100 to 1,400 registered sites between them
Finished-dose manufacturers, Europe and the UK
A larger and more fragmented base than the United States, with national champions in most markets. Certificates of suitability carry weight here that a US filing alone does not, so the technical seat opens the door.
Who signs: procurement director, qualified person or head of quality, regulatory affairs manager, and the formulation lead who specifies the source.
1,500 to 2,000
companies holding manufacturing authorizations across the EU and the UK; roughly 3,500 to 4,500 authorized sites between them
Consumer health and over-the-counter brand owners
They own the label and outsource the manufacture, so they never appear on a register of drug manufacturers. They still specify the ingredient source, and increasingly want a second one named before a launch.
Who signs: director of external supply, category research and development lead, procurement director, and regulatory affairs for label claims.
700 to 1,000
US and European consumer health companies and private label marketers that own the brand and outsource production
Contract manufacturers and development organizations
The segment that buys on behalf of everyone above and rarely gets approached directly, because the assumption is that the brand owner specifies the source. Often they do not.
Who signs: sourcing manager, technical services director, and the business development lead who owns the customer formulation.
400 to 600
North American and European contract manufacturers of solid dose, liquid and semi-solid products
Discovery chemistry and custom synthesis buyers
A completely separate audience from everything above. They buy building blocks and route development by the program, decide quickly, and never appear on an ingredient distributor's customer list.
Who signs: head of chemistry, director of external research or outsourcing, chief scientific officer at smaller companies, and procurement once orders repeat.
2,500 to 3,500
small and mid-cap biotech and pharmaceutical companies in the US and Europe running active discovery chemistry programs
Formulators across the wider regulated-adjacent markets
Latin America, the Middle East, North Africa and Southeast Asia, where a US or European dossier is treated as the qualifying standard. Wide, uneven, and the segment where public registers are thinnest, so this band is deliberately loose.
Who signs: technical director, import and regulatory manager, and the purchase head who signs.
2,000 to 3,000
domestic formulators in markets that accept a US or European dossier as the qualifying standard

Where the openings are

1
A dossier is a reach asset only if the right seat knows it exists. Regulatory affairs is the seat that values a filed master file or a certificate of suitability. Procurement is the seat that signs the order. A channel aimed at one of them arrives with half the argument, and which half depends on the door it came through.
2
Second sourcing is a moment, not a cycle. A supply interruption at an incumbent, a regulatory action against a competing site, an audit that fails, a new formulation entering scale-up. Watching a few thousand named formulators for that moment is mechanical work, and it is the one thing a distributor relationship cannot do on your behalf.
3
The custom chemistry line has a different buyer entirely. Chemistry heads at small biotech do not walk a bulk ingredient trade floor and do not sit on any distributor list. They are reachable, they decide quickly, and in this category that audience is usually served by neither of the channels that reach the formulators.
4
A trade show is one door, once a year. Everything on this page is reachable on a schedule instead. Across the segments here that is roughly 7,500 to 11,000 companies, each with two or three named seats worth knowing before the qualification conversation ever starts.
Built from public market data covering registered pharmaceutical manufacturers and authorized manufacturing sites across the regulated markets, counts banded deliberately. Sites and companies are not the same thing and one company often operates several, so those two lines are counted separately. Registers cover licensed manufacturing rather than brand ownership, so the label owner layer is described rather than enumerated. Coverage outside the US and Europe is thinner and those bands are wider on purpose.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com